Sign up for a daily newsletter defining what matters in business and markets


Activist puts pressure on Stada takeover

Activist investor Elliott Management said today that it wants Bain Capital and Cinven to pay at least €74.40 per share for its 15.2% fully-diluted stake in Stada, the German generic pharma company that the private equity firms have agreed to buy at an enterprise value of around €5.3 billion, or €66.25 per share.

Why it matters: Bain and Cinven right now are paying a lot of money without receiving full control in return. The firms had sweetened their initial offer to win 63% of shareholder approval at the €66.25 per share price, but German law requires 75% for full control. In other words, Elliott has them over a barrel — unless the firms gamble that fewer than half of Stada shares are represented at the next shareholder meeting, which would let them hit the 75% mark. If they want to pay Elliott its demanded price within a year of the deal closing, then they'd have to pay the same to everyone else, pushing the total value from €5.3 billion to around €5.7 billion.

Bottom line: Expect Bain and Cinven to bite the bullet here, as Stada shares today were trading even higher than Elliott's asking price.